-+ 0.00%
-+ 0.00%
-+ 0.00%
Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion upfront
Share
Listen to the news
Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion upfront
  • Johnson & Johnson agreed to acquire eye-disease drug developer Ollin Biosciences for $2.2 billion upfront.
  • Regulatory and commercial milestones could reach approximately $1.13 billion; closing is expected before the end of 2026.
  • The acquisition would add OLN324, an investigational bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema, to its pipeline.
  • Blackstone Life Sciences will provide $750 million over multiple years to fully fund OLN324’s Phase 3 development, contingent on acquisition closing.
  • In return, Blackstone will be eligible for regulatory and sales milestone payments, as well as single-digit royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20261116907414) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending